4. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999;60(Suppl 12):22-23.
5. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;11:CD006633
6. Meltzer HY. Treatment-resistant schizophrenia--the role of clozapine. Curr Med Res Opin 1997;14:1-20.
8. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
9. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health 2014;17:33-37.
10. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-378.
11. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93.
12. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56.
13. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61(Suppl 8):14-17. discussion 18-19.
14. Bellissima BL, Tingle MD, Cicović A, Alawami M, Kenedi C. A systematic review of clozapine-induced myocarditis. Int J Cardiol 2018;259:122-129.
15. Zimbron J, Khandaker GM, Toschi C, Jones PB, Fernandez-Egea E. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. Eur Neuropsychopharmacol 2016;26:1353-1365.
17. Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. Hoboken: John Wiley & Sons; 2021.
18. Lindström LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77:524-529.
19. Juul Povlsen U, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185.
21. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
26. Desmarais JE, Beauclair L, Margolese HC. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther 2011;17:750-760.
28. Lam YW, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001;62(Suppl 5):18-22. discussion 23-24.
29. Bobo WV, Stovall JA, Knostman M, Koestner J, Shelton RC. Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data. Am J Health Syst Pharm 2010;67:27-37.
30. Paton C. Generic clozapine: outcomes after switching formulations. Br J Psychiatry 2006;189:184-185.
31. Alvarez CA, Mascarenas C, Timmerman I. Increasing psychosis in a patient switched from clozaril to generic clozapine. Am J Psychiatry 2006;163:746
32. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001;62(Suppl 5):14-17. discussion 23-24.
33. Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001;23:1720-1731.
34. Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Focus 2014;12:235-243.
35. Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci 2015;69:440-447.
36. Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, et al. Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials. J Affect Disord 2015;180:179-184.
37. Subramanian S, Völlm BA, Huband N. Clozapine dose for schizophrenia. Cochrane Database Syst Rev 2017;6:CD009555
38. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011;123:411-422.
39. Murphy B, Long C, Paton C. Maintenance doses for clozapine. Psychiatr Bull 1998;22:12-14.
41. Ruan CJ, Zang YN, Wang CY, Cheng YH, Sun C, Spina E, et al. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol 2019;39:135-144.
43. Kang N, Kim SH, Kim J, Kim S, Jang J, Yoon H, et al. Association between initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital. Schizophr Res 2023;Aug 24 [Epub].
https://doi.org/10.1016/j.schres.2023.08.001.
44. Wang C, Li L. Proper use of clozapine: experiences in China. Shanghai Arch Psychiatry 2012;24:108-109.
45. Inada K, Oshibuchi H, Ishigooka J, Nishimura K. Analysis of clozapine use and safety by using comprehensive national data from the Japanese clozapine patient monitoring service. J Clin Psychopharmacol 2018;38:302-306.
47. Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005;20:163-168.
49. Grover S, Chakrabarti S, Kulhara P, Avasthi A. Clinical practice guidelines for management of schizophrenia. Indian J Psychiatry 2017;59(Suppl 1):S19-S33.
53. Yi W, She S, Zhang J, Wu H, Zheng Y, Ning Y. Clozapine use in patients with early-stage schizophrenia in a Chinese psychiatric hospital. Neuropsychiatr Dis Treat 2020;16:2827-2836.
54. Verdoux H, Pambrun E. Clozapine use pattern in persons with and without treatment for Parkinson’s disease in real-world conditions: a naturalistic study in a community-based sample. Acta Psychiatr Scand 2014;130:487-497.
55. Bartoli F, Crocamo C, Di Brita C, Esposito G, Tabacchi TI, Verrengia E, et al. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: a meta-analysis. J Psychiatr Res 2019;108:24-33.
58. Mao YM, Zhang MD. Augmentation with antidepressants in schizophrenia treatment: benefit or risk. Neuropsychiatr Dis Treat 2015;11:701-713.
59. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003;59:49-57.
60. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116-1121.
61. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273-1276.
62. Strom BL. Generic drug substitution revisited. N Engl J Med 1987;316:1456-1462.